CD8A and neoplasm: Next, using tetramers for a tumor-rejection, endogenous retroviral antigen, p15E, and an immunodominant vaccinia antigen, B8R, we examined the time course of CD8+ T cell receptor specificity following oncolytic virotherapy (Figures 3A–D).